MSc Project Management Graduate 2012, PRINCE2 Practitioner, APMP, Winner of APM Scottish Project Challenge 2012, Recipient of Technology Strategy Board start-up Grant 2013. Risk Management Product of the year 2013 with Datatecnics. Risk Management Innovation of the year 2015 with Datatecnics (beating Google!) Specialisms: Projects - especially how they relate to strategy; start-up phase; business case design; Supply Chains Direct message me here or on: LinkedIn: http://www.linkedin.com/in/ABHussain New Twitter account: @AbuB_Hussain
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
I am a reformed and recovering management consultant who, through multiple client engagements, applies deep exposure to the upstream and midstream oil and gas industry to create a picture of where these businesses will be in the next two years. With a background in both engineering and finance, I approach investing through a quantitative value approach for the medium and long term horizon.
The investment return profile looks to generate anywhere between 25 and 250 percent within a 12 to 36 month window and minimizes risk by focusing on businesses whose equity is liquid, and are large enough to allow a significant placement of investment assets (generally businesses with total enterprise values in excess of $250mm). The key elements of my investment style are:
1. Is there even the slightest chance the company is going bankrupt? If not, I just stop. I want stuff I can hang on to for long periods without significant risk.
2. Are the managers real artisans in their fields or have they fallen prey to the two most common corporate diseases: (a) their professional management activities are more important that the growth of the company or (b) their skills as financial engineers building masterpieces of leverage are more interesting to them than running a boring business. If not, I just stop. I want people running my investment that I can trust. Included in this category is skin in the game… they better own some measurable percentage of the business so that their own personal fortunes are tied up in it.
3. Is the business they are in one I could explain in under 30 minutes to my 10 year old son? For example, they suck natural gas out of the ground and sell it to whomever will give them the most for it. If not, I just stop. I want stuff I can understand without twisting my brain into a pretzel.
4. Do they build and/or sell stuff that during times of economic recession are truly discretionary items? If they are, I just stop. I want stuff that makes/sells things people need rain or shine.
Fundamentally, I believe self-directed investors can use their own experience and powers of understanding to make exceptional investments on their own, without turning to the professional investment advisory community... and obtain a much better return profile on their assets in the process. I like discovering value, whether because of cyclical down-on-hard-luck stories or secular growth stories and highlighting why I believe they are so.
Patience, low investment position turnover, true understanding of real value of a business, and the power of geometric compounding are the things for which I strive.
I have a private small company with a few different revenue streams. I survive off of one particular stream and invest the other smaller streams into the market.
I consider myself a longterm value investor and am not risk averse. I have three seperate portfolios each holding one third of my capital.
My goal was to create a multiframed method of analysis that might allow the average retail investor to pick investments that have a high probability of doubling or tripling. I am willing to cut against the grain and take contrarian deep value bets based on price value inefficiencies. I would like to compound at 30% average yearly gains in an all of my accounts. I have had 2 years of compounding my money at over 300% in these accounts so I would be ahead of my current benchmarks. As of end of 2013.
However, I do not expect to be able to repeat my results over the long term by trading. In fact I expect to sometimes underperform the market as many of my ideas might take time to come to fruition. I will often use arbitrage opportunities or short term swings for smaller gains. I am working on fine tuning my methodology but I believe it is unique and should produce the minimum average of 30%. I am currently ahead in this race and can withstand a correction as my portfolio grows quickly. I am also willing to get defensive if need be to protect capital or even go 50%cash. I run this as a very concentrated portfolio.
One third of my capital goes in a DRIP that I average in monthly to seven companies. I change these companies yearly based on valuation and position size. I grow positions here over time and never want to hold more than 30 companies in this account.
One third goes into long term companies that I see huge growth potential.
One third is in speculative bio-tech, tech and just about anything else where I can understand the financial statement sheets on and has great possible momentum and catalysts.
I often find myself going against the current trends in the market as I see opportunity in others fear. That said I seem to invest in around 15 stocks at a time and try to focus investments into the company at the best value. I hope to earn a healthy return over the next ten years to twenty years.
I am also interested in working in the industry as a career change and am always open to advice. Anyone out there want a 36 year old intern with advanced degrees in other areas?
My main skills are finding deep value opportunities and lucrative swing trade opportunities. I seem to have found a lot of bottom entries even in today's markets. I am willing to learn, enjoy games/game theory, love to read and solve problems.
I am working on starting a limited partnership for 2015 or 2016 so that I can share my gifts with family and friends.
"What looks like a horrible disaster now could be an awesome opportunity." "Buy Cheap when the big funds and others are giving it away"
All the Best,
StockMatusow.com Writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Scott has his own online talk show which can be heard at www.scottmatusow.com/radio .
During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about.
Other places you can follow Scott are:
Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com.
Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector.
Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations.
As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points.
Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis
Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com
Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.
Michael can be followed at www.twitter.com/MMK_3399 @MMK_3399
Graduated from University of Cambridge with BA & MA in Economics. Worked in European Equities for 12 years. Previously at Credit Suisse in London in their European Equity Hedge Fund Group. Move to NYC with ING to build out European Equity platform servicing hedge funds. Left to launch a Single Family Housing Partnership focused on the high growth South East USA. Portfolio being built out in Charlotte, North Carolina.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
I have been an active investor for almost 20 years. My main focus is on high-yield stocks, particularly MLPs, and high-growth oil companies in the Eagle Ford shale. I have a portion of my portfolio allocated to short-term trading, with a focus on over-reactions to company news and directional plays on VIX-based ETFs. I am happy to answer just about any question sent my way, especially from those new to the stock market.
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
"Nishkama Capital LLC ("Nishkama") is an investment manager with a long / short equity strategy with a focus in the Technology, Media and Telecom (“TMT”) sectors. Nishkama also makes investments in other sectors such as Consumer, Industrials and Financials. The Founder is the Author of "The Emotionally Intelligent Investor: How Self-Awareness, Empathy and Intuition Drive Performance."
Junior Financial Reporter at Capital Ladder Advisory Group LLC.
Undergraduate at Northwestern University: B.A. in Economics, Mathematical Methods in the Social Sciences, Mathematics, expected June 2015,
Analyst and Fund Manager with almost 20 years investment experience. Coverage includes a variety of industries, with a focus on technology.
Particularly focused on value stocks, poorly understood or under-followed situations, and contrarian perspectives.
Primarily invest in special situations with value that is poorly understood or not fully appreciated, or where we believe there is a highly asymetric risk/reward profile. Also look for long/short ideas in mid/larger cap names where we believe we have a variant view, and the market is dramatically mispricing value.
Follow me on Twitter @valinsights
Markman Advisors specializes in the strategic analysis of investment opportunities presented by intellectual property—and in particular, patent—litigation activities. We are all USPTO-registered patent attorneys with decades of combined experience in patent litigation, licensing and procurement. After many years practicing at some of the world’s largest and well-known law firms, we established and now run a premier intellectual-property boutique law firm, where we continue to practice patent litigation.
We have litigated numerous high-stakes patent cases in federal district courts throughout the country, as well as at the appellate level before the Federal Circuit. We are also experienced in USPTO proceedings, and have advised clients across a wide swath of technical areas with respect to patent-related matters.
Our base of former and current legal clients is diverse, from technology start-ups to some of the world’s largest and most well-known corporations. Collectively, we have led those clients through numerous Markman hearings, summary judgment motions, trials and appeals – on both the offensive and defensive sides of a case.
Our patent litigation experience, coupled with our knowledge of the market for "patent play" stocks, is the alpha we bring to each patent litigation-driven investment opportunity.
PhD in Computational Physics. Developing new models for stock trading (focusing on long SVXY). Predicting future accurately enough for trading purposes is surprisingly difficult... :)
Contrarian investment philosophy. I am in particular interested in undervalued technology stocks with multiple x upside potential and limited downside risk.
I am currently long $MSFT, $LNVGY, $INTC, $CRAY, $VRNG, $OCAT, $F, $TLT, $ALU and $NOK. $NOK (and now $ALU) are still the largest position in my portfolio, although I sold 70% of my $NOK position since the Devices and Services deal with Microsoft was announced. $NOK/ALU, and $TLT are currently my largest individual stock/ETF positions.
I also swing trade inverse volatility (long $SVXY) depending on market trends. I do not touch $VIX or other direct volatility products under any circumstances.
Additional disclosure: My comments, Stocktalks, articles etc are not an endorsement to buy or sell securities. Investing in securities carries with it very high risks. The information contained within my articles and commentary is for informational purposes only and is subject to change at any time. Do your own due diligence and consult with a licensed professional before making any investment decisions.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha iPhone app (http://itunes.apple.com/app/seeking-alpha-portfolio), our Real Time email alert product (http://seekingalpha.com/real-time-alerts), and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha as well as on Twitter @SA_Product_Team. We look forward to your input and feedback!
SA Product Team
We have over 60 years of investment analysis experience. We have published investment research from the perspective of the buy side and the sell side. Our work has been used by institutions managing over $1 trillion in aggregate. We have published reports from both the long and short perspective and have worked with the largest short selling mutual fund in the world. We are long term value investors. It is our belief that, contrary to popular opinion, most individual investors and patient professional investors have the best opportunity since the beginning of our investment career to beat institutional and mutual fund managers in terms of risk adjusted performance. The "Information Arbitrage" advantage institutional investors have had is mostly eliminated, while the individual investor still can maintain an edge with "Time Arbitrage". Our goal is to provide institutional quality buy side articles that educate and stimulate investors in the hope of improving their returns. We also are willing to mentor young analysis who wish to improve their analytical skills.
22 years equity experience at top investment banks in London and asset managers in Europe. I worked on Tech stocks at the research department of the Credit Suisse Tech Group in London till 2002. After that I switched to the Buy side. Last 5 years as head analyst at the Global Equity Fund of Robeco in Rotterdam that manages 9 bln USD in global equity. My focus is long term valuation techniques and rigorous financial analysis that identifies short term exaggerations in the market.